Louisiana Center for Bleeding and Clotting Disorders, Tulane University Medical Center, New Orleans, Louisiana 70112, USA.
Am J Hematol. 2012 May;87 Suppl 1:S23-6. doi: 10.1002/ajh.23191. Epub 2012 Apr 4.
High-titer inhibitors represent the greatest management challenge faced by clinicians who treat patients with hemophilia A, as bleeding episodes no longer respond to standard factor VIII replacement therapy. Over the last seven decades, major strides have been made in inhibitor treatment. This article focuses on the seminal clinical observations and studies that provided the foundation for these advances in hemophilia care.
高滴度抑制剂代表着治疗 A 型血友病患者的临床医生所面临的最大管理挑战,因为出血事件不再对标准的凝血因子 VIII 替代疗法产生反应。在过去的七十年中,在抑制剂治疗方面取得了重大进展。本文重点介绍了为血友病治疗的这些进展提供基础的重要临床观察和研究。